Delving into the Latest Updates on KMHH-03 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

KMHH 03, KMHH-03, KMHH03

Target

HSP90B1

Mechanism

HSP90B1 inhibitors(Endoplasmin inhibitors)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication

Advanced breast cancer

Inactive Indication-

Originator Organization

Beijing Kangming Hanghui Biotechnology Co Ltd.

Active Organization

Beijing Kangming Hanghui Biotechnology Co Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：（1）评价注射用KMHH-03在晚期乳腺癌受试者中的安全性及耐受性；（2）确定注射用KMHH-03单次给药的剂量限制性毒性（DLT）与最大耐受剂量（MTD）。次要目的：（1）评价注射用KMHH-03在晚期乳腺癌受试者中的药代动力学（PK）特征；（2）评估注射用KMHH-03在晚期乳腺癌受试者中的免疫原性；（3）观察注射用KMHH-03在晚期乳腺癌受试者中的初步疗效，为后续临床试验推荐剂量和给药方案提供依据。

[Translation]

Primary objectives: (1) To evaluate the safety and tolerability of KMHH-03 for injection in subjects with advanced breast cancer; (2) To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of a single dose of KMHH-03 for injection. Secondary objectives: (1) To evaluate the pharmacokinetic (PK) characteristics of KMHH-03 for injection in subjects with advanced breast cancer; (2) To evaluate the immunogenicity of KMHH-03 for injection in subjects with advanced breast cancer; (3) To observe the preliminary efficacy of KMHH-03 for injection in subjects with advanced breast cancer and provide a basis for the recommended dose and dosing regimen for subsequent clinical trials.

Start Date11 Oct 2023

Sponsor / Collaborator

Beijing Kangming Hanghui Biotechnology Co Ltd.

100 Clinical Results associated with KMHH-03

Login to view more data

100 Translational Medicine associated with KMHH-03

Login to view more data

100 Patents (Medical) associated with KMHH-03

Login to view more data

100 Deals associated with KMHH-03

Login to view more data